Publications

Xu et al. showed that elevated BMI, BSA, body weight, and basal metabolic rate are associated with more severe PsO and diminished treatment efficacy, especially for those treated with biologics. Authors investigated the associations of BMI, basal metabolic rate, BSA, and body weight with baseline PsO severity and therapeutic response across different treatment modalities.

Lin et al. compared the risk of CVD in patients with psoriasis who were prescribed biologics or oral therapies and assessed the association between different classes of biologics and CVD risk. Patients with psoriasis-prescribed biologics exhibited a reduced risk of incident CVDs compared with those receiving oral antipsoriatic drugs.

Chen et al. investigated the risk of MACE and VTE among patients with biologic-naïve psoriasis or PsA receiving biologic therapy. No significant difference in the risks of MACE and VTE was found between new biologics (IL-17i, IL-12/23i, or IL-23i) and TNFi.

Floris et al. conducted a monocentric cohort study to assess the impact of biologic treatment on the development of PsA in patients with PsO. Treatment with biologics significantly reduced the likelihood of PsA development, with lower prevalence observed across different biologic classes and patterns of joint involvement.

Tsai et al. observed no significant difference in the incidence of psoriatic arthritis among psoriasis patients treated with IL-23 inhibitors compared to IL-12/23 inhibitors, although there was a numerically lower PsA risk with IL-23 inhibitors. Results indicate both therapies are similarly effective for PsO management.